-transparent.png){kind=logo}
The antiemetic effect of alizapride was evaluated in 50 patients with advanced cancer undergoing chemotherapy with cis-platinum. Our results suggest that alizapride, in a dose of 800 or 900 mg, significantly alleviates nausea and emesis. In a preliminary study, we had established that, without antiemetic therapy, the same patients all suffered from emesis. On the whole, alizapride was well tolerated ; no major side-effects were recorded.
Related Publications
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
February 1982,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
March 1987,
La Clinica terapeutica,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
February 1982,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
January 1984,
Arzneimittel-Forschung,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
February 1982,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
January 1985,
European journal of clinical pharmacology,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
January 1990,
Giornale italiano di oncologia,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
February 1982,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
February 1982,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Cupissol, and
F Favier, and
C Favier, and
B Serrou
January 1988,
Cancer chemotherapy and pharmacology,
